These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

677 related articles for article (PubMed ID: 29650706)

  • 1. Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction.
    Abernethy A; Raza S; Sun JL; Anstrom KJ; Tracy R; Steiner J; VanBuren P; LeWinter MM
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29650706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
    Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.
    Tromp J; Khan MA; Klip IT; Meyer S; de Boer RA; Jaarsma T; Hillege H; van Veldhuisen DJ; van der Meer P; Voors AA
    J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28360225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Diastolic Dysfunction with N-terminal Pro-B-type Natriuretic Peptide Level in Heart Failure Patients with Preserved Ejection Fraction.
    Islam MN; Chowdhury MS; Paul GK; Debnath RC; Shakil SS
    Mymensingh Med J; 2019 Apr; 28(2):333-346. PubMed ID: 31086148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
    Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
    Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
    Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
    Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of ST2 and B-type natriuretic peptide in diabetic patients with acute heart failure: relation with ventricular stiffness and outcome.
    Ruocco G; Evangelista I; Franci B; Lucani B; Martini S; Nuti R; Palazzuoli A
    J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):81-90. PubMed ID: 30540645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction.
    Hage C; Bjerre M; Frystyk J; Gu HF; Brismar K; Donal E; Daubert JC; Linde C; Lund LH
    Am J Cardiol; 2018 Jun; 121(12):1558-1566. PubMed ID: 29622288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.
    Bishu K; Deswal A; Chen HH; LeWinter MM; Lewis GD; Semigran MJ; Borlaug BA; McNulty S; Hernandez AF; Braunwald E; Redfield MM
    Am Heart J; 2012 Nov; 164(5):763-770.e3. PubMed ID: 23137508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study.
    Savarese G; Donal E; Hage C; Oger E; Persson H; Daubert JC; Linde C; Lund LH;
    Int J Cardiol; 2017 Jan; 226():65-70. PubMed ID: 27788392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; McKie PM; Dunlay SM; Stevens SR; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization.
    Nikolova AP; Hitzeman TC; Baum R; Caldaruse AM; Agvanian S; Xie Y; Geft DR; Chang DH; Moriguchi JD; Hage A; Azarbal B; Czer LS; Kittleson MM; Patel JK; Wu AHB; Kobashigawa JA; Hamilton M; Hong T; Shaw RM
    JAMA Cardiol; 2018 Dec; 3(12):1206-1210. PubMed ID: 30383171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction.
    Buckley LF; Canada JM; Del Buono MG; Carbone S; Trankle CR; Billingsley H; Kadariya D; Arena R; Van Tassell BW; Abbate A
    ESC Heart Fail; 2018 Apr; 5(2):372-378. PubMed ID: 29345112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction.
    Kanagala P; Arnold JR; Cheng ASH; Singh A; Khan JN; Gulsin GS; Yang J; Zhao L; Gupta P; Squire IB; Ng LL; McCann GP
    Int J Cardiovasc Imaging; 2020 Jan; 36(1):101-110. PubMed ID: 31401742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
    Trippel TD; Van Linthout S; Westermann D; Lindhorst R; Sandek A; Ernst S; Bobenko A; Kasner M; Spillmann F; González A; López B; Ravassa S; Pieske B; Paulus WJ; Díez J; Edelmann F; Tschöpe C
    Eur J Heart Fail; 2018 Mar; 20(3):460-470. PubMed ID: 28891228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction.
    Matsubara J; Sugiyama S; Nozaki T; Akiyama E; Matsuzawa Y; Kurokawa H; Maeda H; Fujisue K; Sugamura K; Yamamoto E; Matsui K; Jinnouchi H; Ogawa H
    J Am Heart Assoc; 2014 Jul; 3(4):. PubMed ID: 25012287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion.
    Van Aelst LNL; Arrigo M; Placido R; Akiyama E; Girerd N; Zannad F; Manivet P; Rossignol P; Badoz M; Sadoune M; Launay JM; Gayat E; Lam CSP; Cohen-Solal A; Mebazaa A; Seronde MF
    Eur J Heart Fail; 2018 Apr; 20(4):738-747. PubMed ID: 29251818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction.
    Nolte K; Herrmann-Lingen C; Platschek L; Holzendorf V; Pilz S; Tomaschitz A; Düngen HD; Angermann CE; Hasenfuß G; Pieske B; Wachter R; Edelmann F
    ESC Heart Fail; 2019 Apr; 6(2):262-270. PubMed ID: 30784226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction.
    DuBrock HM; AbouEzzeddine OF; Redfield MM
    PLoS One; 2018; 13(8):e0201836. PubMed ID: 30114262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.